Skip To The Main Content

PDA Webinar: Applying the New June 2020 FDA Guidance on Responding to COVID-19 Infection in Employees in Manufacturing

Sponsored by Johnson & Johnson

Aug 24, 2020
11:00 AM
12:30 PM
| Eastern Standard Time
  • Virtual
  • Webinar
  • Online
  • The Americas


Sponsored by Johnson & Johnson

The new FDA guidance provides important information related to performance of risk assessment of the current industry viral control strategies for SARS-CoV-2 virus related to cell culture manufacturing. According to the guidance, this risk assessment may include, but not be limited to the leverage of existing available information on the following:

  • The potential of the SARS-CoV-2 virus to replicate in production cell lines.
  • Whether current cell bank and harvest viral testing would detect SARS-CoV-2.
  • The effectiveness of viral clearance and inactivation steps for SARS-CoV-2.
  • Controls in buffer and media preparation areas.

This and other important areas covered in the guidance will be discussed including, general risk assessment on the manufacturing process when employees are identified as having had COVID-19, the exclusion of potentially infected employees from the workplace, the level of documentation of cleaning and disinfection in non-GMP areas, and the FDA expectation of the response by industry of viral events that may include employees identified as having had COVID-19 infections.

This webinar is intended to provide attendees the opportunity to better understand the expectations outlined in the guidance through a general discussion of the guidance as well as an open Q&A session that has been extended to allow ample time for questions. The panel will consist of both FDA and Industry representatives.

Panelists include:
  • Paul Barone, PhD, Associate Director, Biomanufacturing Research Program at the MIT Center for Biomedical Innovation
  • Tony Cundell, PhD, Principal Consultant, Microbiological Consulting LLC
  • Thomas Kreil, PhD, Vice President Global Head Pathogen Safety, Takeda
  • Alonza Cruse, Director, Office of Pharmaceutical Quality Operations, ORA, U.S. FDA
  • Peter Qiu, PhD, Division Director (Acting), Office of Pharmaceutical Manufacturing Assessment, U.S. FDA
  • Joel Welch, PhD, Associate Director for Biosimilar and Regulatory Policy (Acting), OBP, U.S. FDA

Registration Fees

Register Now

This webinar is free for PDA Members

The price for non-members is $20.

Got a Question? We have answers

Contact Us
Become a Sponsor

Interested in becoming a sponsor? Learn about opportunities and benefits.

Request Information


Become an Exhibitor

Interested in becoming an exhibitor? Learn about opportunities and benefits.

Request Information

Attendee List Email Scam

Unfortunately, emails are circulating that offer to sell attendee lists for many of PDA’s conferences and events. These emails are sent by scammers.

Note: PDA does not sell its exhibitor or attendee lists, and no third-party is authorized to distribute or sell any lists related to our events. Statements claiming to offer our attendee lists are fraudulent. If you receive emails that propose to sell PDA conference attendee lists, do not engage with the sender and delete the message immediately.

Media Partners

PDA Members Save Substantially